Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
Buy
74
QGEN Quote, Financials, Valuation and Earnings
Last price:
$55.49
Seasonality move
:
1.83%
Day range:
$46.07 - $57.82
52-week range:
$37.63 - $57.82
Dividend yield:
0.45%
P/E ratio:
28.42x
P/S ratio:
5.56x
P/B ratio:
3.13x
Volume:
15M
Avg. volume:
1.8M
1-year change:
17.2%
Market cap:
$11.4B
Revenue:
$2B
EPS (TTM):
$1.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
$528.5M | $0.62 | 5.73% | 39.86% | $52.87 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
IFRX
InflaRx NV
|
$30.4K | -$0.17 | -74.55% | -37.98% | $10.31 |
|
LENZ
LENZ Therapeutics, Inc.
|
$1.6M | -$0.96 | -7.14% | -69.46% | $53.71 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.62 | -- | -23.21% | $55.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
$55.45 | $52.87 | $11.4B | 28.42x | $2.29 | 0.45% | 5.56x |
|
CDT
CDT Equity, Inc.
|
$1.47 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
IFRX
InflaRx NV
|
$0.99 | $10.31 | $67M | -- | $0.00 | 0% | 305.58x |
|
LENZ
LENZ Therapeutics, Inc.
|
$19.38 | $53.71 | $606.4M | -- | $1.03 | 0% | 30.91x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
$33.23 | $55.67 | $1.6B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
36.82% | 0.399 | 21.96% | 2.12x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.944 | 27% | 1.13x |
|
IFRX
InflaRx NV
|
2.1% | -0.265 | 1.26% | 2.34x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.162 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.530 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
$329.1M | $137.3M | 7.77% | 11.48% | 25.78% | $114.6M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
QIAGEN NV vs. Competitors
-
Which has Higher Returns QGEN or CDT?
CDT Equity, Inc. has a net margin of 24.42% compared to QIAGEN NV's net margin of --. QIAGEN NV's return on equity of 11.48% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About QGEN or CDT?
QIAGEN NV has a consensus price target of $52.87, signalling downside risk potential of -4.32%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that QIAGEN NV has higher upside potential than CDT Equity, Inc., analysts believe QIAGEN NV is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 CDTCDT Equity, Inc.0 0 0 -
Is QGEN or CDT More Risky?
QIAGEN NV has a beta of 0.668, which suggesting that the stock is 33.248% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or CDT?
QIAGEN NV has a quarterly dividend of $2.29 per share corresponding to a yield of 0.45%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QIAGEN NV pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or CDT?
QIAGEN NV quarterly revenues are $532.6M, which are larger than CDT Equity, Inc. quarterly revenues of --. QIAGEN NV's net income of $130M is higher than CDT Equity, Inc.'s net income of -$7.1M. Notably, QIAGEN NV's price-to-earnings ratio is 28.42x while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 5.56x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV5.56x 28.42x $532.6M $130M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns QGEN or IFRX?
InflaRx NV has a net margin of 24.42% compared to QIAGEN NV's net margin of -51538.49%. QIAGEN NV's return on equity of 11.48% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About QGEN or IFRX?
QIAGEN NV has a consensus price target of $52.87, signalling downside risk potential of -4.32%. On the other hand InflaRx NV has an analysts' consensus of $10.31 which suggests that it could grow by 942.24%. Given that InflaRx NV has higher upside potential than QIAGEN NV, analysts believe InflaRx NV is more attractive than QIAGEN NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 IFRXInflaRx NV5 2 0 -
Is QGEN or IFRX More Risky?
QIAGEN NV has a beta of 0.668, which suggesting that the stock is 33.248% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.443, suggesting its more volatile than the S&P 500 by 44.312%.
-
Which is a Better Dividend Stock QGEN or IFRX?
QIAGEN NV has a quarterly dividend of $2.29 per share corresponding to a yield of 0.45%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QIAGEN NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or IFRX?
QIAGEN NV quarterly revenues are $532.6M, which are larger than InflaRx NV quarterly revenues of $27.8K. QIAGEN NV's net income of $130M is higher than InflaRx NV's net income of -$14.3M. Notably, QIAGEN NV's price-to-earnings ratio is 28.42x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 5.56x versus 305.58x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV5.56x 28.42x $532.6M $130M IFRXInflaRx NV305.58x -- $27.8K -$14.3M
-
Which has Higher Returns QGEN or LENZ?
LENZ Therapeutics, Inc. has a net margin of 24.42% compared to QIAGEN NV's net margin of -133.6%. QIAGEN NV's return on equity of 11.48% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About QGEN or LENZ?
QIAGEN NV has a consensus price target of $52.87, signalling downside risk potential of -4.32%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $53.71 which suggests that it could grow by 177.16%. Given that LENZ Therapeutics, Inc. has higher upside potential than QIAGEN NV, analysts believe LENZ Therapeutics, Inc. is more attractive than QIAGEN NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 LENZLENZ Therapeutics, Inc.6 0 0 -
Is QGEN or LENZ More Risky?
QIAGEN NV has a beta of 0.668, which suggesting that the stock is 33.248% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LENZ?
QIAGEN NV has a quarterly dividend of $2.29 per share corresponding to a yield of 0.45%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. QIAGEN NV pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LENZ?
QIAGEN NV quarterly revenues are $532.6M, which are larger than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. QIAGEN NV's net income of $130M is higher than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, QIAGEN NV's price-to-earnings ratio is 28.42x while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 5.56x versus 30.91x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV5.56x 28.42x $532.6M $130M LENZLENZ Therapeutics, Inc.30.91x -- $12.5M -$16.7M
-
Which has Higher Returns QGEN or LIMN?
Liminatus Pharma has a net margin of 24.42% compared to QIAGEN NV's net margin of --. QIAGEN NV's return on equity of 11.48% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About QGEN or LIMN?
QIAGEN NV has a consensus price target of $52.87, signalling downside risk potential of -4.32%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that QIAGEN NV has higher upside potential than Liminatus Pharma, analysts believe QIAGEN NV is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 LIMNLiminatus Pharma0 0 0 -
Is QGEN or LIMN More Risky?
QIAGEN NV has a beta of 0.668, which suggesting that the stock is 33.248% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LIMN?
QIAGEN NV has a quarterly dividend of $2.29 per share corresponding to a yield of 0.45%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QIAGEN NV pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LIMN?
QIAGEN NV quarterly revenues are $532.6M, which are larger than Liminatus Pharma quarterly revenues of --. QIAGEN NV's net income of $130M is higher than Liminatus Pharma's net income of --. Notably, QIAGEN NV's price-to-earnings ratio is 28.42x while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 5.56x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV5.56x 28.42x $532.6M $130M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns QGEN or ORKA?
Oruka Therapeutics, Inc. has a net margin of 24.42% compared to QIAGEN NV's net margin of --. QIAGEN NV's return on equity of 11.48% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About QGEN or ORKA?
QIAGEN NV has a consensus price target of $52.87, signalling downside risk potential of -4.32%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $55.67 which suggests that it could grow by 67.52%. Given that Oruka Therapeutics, Inc. has higher upside potential than QIAGEN NV, analysts believe Oruka Therapeutics, Inc. is more attractive than QIAGEN NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 ORKAOruka Therapeutics, Inc.11 0 0 -
Is QGEN or ORKA More Risky?
QIAGEN NV has a beta of 0.668, which suggesting that the stock is 33.248% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.394, suggesting its less volatile than the S&P 500 by 139.44%.
-
Which is a Better Dividend Stock QGEN or ORKA?
QIAGEN NV has a quarterly dividend of $2.29 per share corresponding to a yield of 0.45%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. QIAGEN NV pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or ORKA?
QIAGEN NV quarterly revenues are $532.6M, which are larger than Oruka Therapeutics, Inc. quarterly revenues of --. QIAGEN NV's net income of $130M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, QIAGEN NV's price-to-earnings ratio is 28.42x while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 5.56x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV5.56x 28.42x $532.6M $130M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Is Progressive a Good Stock to Own?
After faring well for multiple years, shares of property and…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 61x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Sell
42
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RAPT alert for Jan 21
Rapt Therapeutics, Inc. [RAPT] is up 63.93% over the past day.
Buy
73
HYMC alert for Jan 21
Hycroft Mining Holding Corp. [HYMC] is up 23.42% over the past day.
Buy
92
GMINF alert for Jan 21
G Mining Ventures Corp. [GMINF] is up 17.87% over the past day.
